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Paragangliomas are rare neuroendocrine neoplasms that 
arise from the chromaffin tissue. Tumours originating 
from the sympathetic nervous system are located within 
the adrenal medulla (pheochromocytomas) or sympa-
thetic ganglia in the neck, chest, abdomen, and pelvis, 
and they usually produce catecholamines, while tumours 
arising from the parasympathetic nervous system are 
commonly found in the head, neck, and mediastinum 
and are usually non-secreting. Almost 40% of paragan-
gliomas have a genetic background [1]. They can be as-
sociated with autosomal dominant inheritance mutations 
in one of the genes encoding succinate dehydrogenase 
(SDHB, SDHD, SDHC, SDHA, SDHAF2) or can coexist 
in genetically determined endocrine syndromes such as 
MEN type 2A and 2B, NF1, or VHL. Additional genes 
predisposing to hereditary pheochromocytoma are 
still being discovered that should be investigated when 
searching for the genetic cause of pheochromocytoma in 
affected families. Each of the mutated genes is associated 
with the specific characteristics of clinical features of the 
pheochromocytoma they are responsible for. Therefore, 
usually, the clinical picture may be an indicator of the 
gene that should be searched for pathogenic variants in 
a given patient and their family.
Herein, we present a rare case of a patient with an ag-
gressive, metastatic, hereditary paraganglioma associ-
ated with a pathogenic variant in SDHD and an atypical 
clinical outcome.  
A 69-year-old woman with a history of arterial hy-
pertension and hypothyroidism (after treatment with 
I-131 due to hyperthyroidism) was admitted to the 
Department of Endocrinology in 2015 because of bone 
metastasis of neuroendocrine cancer from an unknown 
primary lesion. The patient had undergone removal of 
the paraganglioma of the right carotid artery in 2008, 
and she had had surgical treatment of an L3 vertebra 
fracture in 2015. During the hospitalisation, biochemical 
data showed a significantly increased concentration of 
chromogranin A 93.6 ng/mL (0–6) and increased excre-
tion of 3-methoxytyramine 15821.6 ug/24 h (N: 0–220) 
in 24-hour urine collection.
The material collected from the L3 vertebral me-
tastasis was re-examined (a diagnosis of metastatic 
neuroendocrine cancer was included in the primary 
histopathological report), and the diagnosis of meta-
static paraganglioma was established. The tumour cells 
expressed synaptophysin and had a Ki-67 index at 9%, 
and no expression of somatostatin receptors was found 
in the neoplastic cells. An active metabolic recurrence of 
paraganglioma in the area of bifurcation of the common 
carotid artery (Fig. 1)/mandibular angle on the right 
side, with massive dissemination to the skeletal system 
(Fig. 2) and the involvement of the chest lymph nodes, 
were visualised in 18F-fluorodeoxyglucose positron 
emission tomography/computed tomography ([18F]
F-FDG PET-CT) (07.12.2015).
In Iodine-131-meta-iodobenzylguanidine ([131I]I-
-MIBG) scintigraphy (23.12.2015), tracer uptake in the 
lower jaw area on the left side, on the neck in the thyroid 
gland topography to the right of the midline of the body, 
and xiphoid process of the sternum in the thoracic spine 
and the plate of the right iliac bone were found (Fig. 3).
The molecular analysis revealed an uncommon 
variant, c.34G>A (p.Gly12Ser), in the SDHD gene. At 
that time point, this variant was of unknown clinical 
significance. The detected variant occurred as a homo-
zygote in Sanger sequencing analysis. Therefore, the 
genetic investigation was complemented by multiplex 
ligation-dependent probe amplification (MLPA), result-
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ing in the detection of a pathogenic alteration — an ex-
tensive gene deletion (encompassing exons 1–3) on one 
allele. Currently, the c.34G>A (p.Gly12Ser) variant is 
classified as benign or probably benign in the NCBI 
ClinVar database.
The patient was referred for therapy with iodine-la-
belled MIBG but unfortunately died due to dissemination.
Genetic testing was performed in the patient’s fam-
ily members. Her son inherited the extensive deletion, 
but because SDHD mutations are paternally inherited 
[2, 3], it should not be evident clinically. The molecular 
analysis was also conducted in his 2 children: genetic 
alterations were excluded in the case of his son but 
confirmed in the case of his daughter — the same 
extensive gene deletion (encompassing exons 1–3) 
with a high probability (approximately 80%) of caus-
ing symptoms of the paraganglioma syndrome. The 
daughter — a 20-year-old woman — was diagnosed 
with a lesion in a sternum indentation a few weeks ago 
and is now undergoing a diagnostic process.
Genetic alterations in the SDHD gene account for 
approximately 9% of all pheochromocytoma/para-
ganglioma cases [1]. Paragangliomas associated with 
SDHD variants develop most often in head and neck 
locations, they are usually benign tumours, and the risk 
of metastatic disease in carriers is approximately 5–7% 
[4, 5]. The above case was characterised by an atypi-
cally aggressive clinical course with relapse and distant 
metastasis 7 years after the initial diagnosis.
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Figure 1. PET/CT imaging with 18F FDG  shows local recurrence 
of paraganglioma. The arrow shows an active metabolic area of 
paraganglioma in the area of bifurcation of the common carotid 
artery/mandibular angle on the right side. (Department of 
Endocrinology Medical College Jagiellonian University Krakow, 
Poland)
Figure 2. PET/CT imaging with 18F FDG. The arrows show 
an active metabolic area of paraganglioma in the area of vertebral 
column and sacroiliac bone. (Department of Endocrinology 
Medical College Jagiellonian University Krakow, Poland)
Figure 3. SPECT/CT imaging with 
131I-MIBG. Accumulation of a tracer in 
the lower jaw area on the left side, on the 
neck in the thyroid gland topography to 
the right of the midline of the body, and 
xiphoid process of the sternum in the 
thoracic spine and the plate of the right. 
(Department of Endocrinology Medical 
College Jagiellonian University Krakow, 
Poland)
